Nevada Health Centers Partners with Javara to Expand Clinical Trial Access, Including Norovirus Vaccine Study
Key Insights
Nevada Health Centers (search) has partnered with Javara (search) since 2023 to conduct fourteen clinical trials in the Carson City area, with six currently ongoing including norovirus vaccine and oral GLP-1 (search) studies.
The norovirus vaccine trial targets adults 60 and older as part of a national study to address a disease responsible for 2,500 annual U.S. outbreaks and 58% of foodborne illnesses.
Clinical trials offer participants access to experimental treatments before widespread availability, with no participation costs and compensation for time and travel expenses.
Nevada Health Centers (search) (NVHC), a federally qualified community health center, has significantly expanded clinical research access for Nevada residents through its partnership with Javara (search), an integrated research organization, since 2023. The collaboration has brought fourteen clinical trial opportunities to the Carson City area, with six studies currently active at the Sierra Nevada Health Center.
Current Clinical Trial Portfolio
The ongoing trials address multiple therapeutic areas including norovirus (search) prevention, diabetes (search) management, malnutrition (search), heart failure (search) prevention, hypothyroidism (search), and COVID-19 (search). According to Dr. Sangeeta Wagner from Nevada Health Centers (search), the partnership aims to provide "opportunities of major biopharmaceutical, clinical research, new, innovative medications" to their patient population.
Norovirus Vaccine Development
A key focus of the current recruitment efforts is the norovirus vaccine clinical trial, targeting participants aged 60 and older. This study represents part of a national effort to develop the first approved vaccine against norovirus (search), a highly contagious pathogen with significant public health impact.
According to CDC (search) data cited by the researchers, norovirus (search) causes 2,500 outbreaks annually in the United States and accounts for 58% of all foodborne illnesses. Dr. Wagner explained the clinical significance: "For most of us, otherwise healthy adults, we can just have a few days of some mild discomfort. But in the vulnerable population, adult patients or those very young, it can lead to dehydration or death."
Currently, no approved vaccine or antiviral treatment exists for norovirus (search), making this research particularly valuable for addressing an unmet medical need.
Oral GLP-1 Alternative
Another significant trial involves an oral GLP-1 (search) medication for adults with diabetes (search) and obesity (search). This research offers a potential alternative to current injectable GLP-1 therapies. "This medication is an oral medication for adults that will help them in the same ways. It's nice because it will give patients the alternative instead of having to inject themselves once a week," Dr. Wagner noted.
Participant Benefits and Eligibility
The clinical trials target specific populations: adults 18 and older for most studies, with the norovirus vaccine trial specifically recruiting participants 60 and older. Conditions of interest include diabetes (search), obesity (search), heart failure (search) prevention, hypothyroidism (search), and COVID-19 (search).
Participants receive several benefits including no-cost participation, compensation for time and travel expenses, and potential access to experimental treatments before they become widely available. All interested individuals undergo a pre-screening process to determine eligibility.
Program Expansion Plans
The success of the Carson City program has prompted plans for statewide expansion to other Nevada Health Centers (search) facilities. However, current recruitment efforts face a time constraint, with application deadlines approaching within 4-6 weeks.
The clinical research program represents a significant step in addressing healthcare access challenges in Nevada while contributing to national drug development efforts. As Dr. Wagner emphasized, these trials are "an essential step in developing new medications and therapies" that could benefit thousands of patients annually.